Glenmark Pharmaceuticals gets FDA approval for Nintedanib Capsules
Glenmark Pharmaceuticals Ltd said that it has secured tentative approval from the US Food and Drug Administration (FDA) for Nintedanib Capsules, 100mg, and 150mg. Nintedanib ... Read More
Glenmark Pharmaceutical launches Tiogiva in UK for COPD treatment
Glenmark Pharmaceutical has announced the UK launch of Tiogiva, a bioequivalent version of Tiotropium Bromide dry powder inhaler (DPI), for the treatment of chronic obstructive ... Read More
Boehringer Ingelheim to acquire NBE-Therapeutics for €1.1bn
Boehringer Ingelheim has entered into a transformative €1.18 billion agreement to acquire NBE-Therapeutics, a clinical-stage biotech company based in Switzerland. This strategic acquisition is set ... Read More
Boehringer Ingelheim expands pets vaccines production facility in Athens
German pharma giant Boehringer Ingelheim has wrapped up the $76 million expansion of its pets vaccines production facility at Athens in Georgia, US. The investment ... Read More
Boehringer Ingelheim acquires Swiss biotech company AMAL Therapeutics
Boehringer Ingelheim acquisition of AMAL Therapeutics : German pharma company Boehringer Ingelheim has acquired Swiss biotech company AMAL Therapeutics for up to EUR325 million, as ... Read More
Boehringer Ingelheim acquires ViraTherapeutics for €210m in strategic cancer immunotherapy expansion
German pharmaceutical powerhouse Boehringer Ingelheim has acquired Austria-based oncolytic virus developer ViraTherapeutics for €210 million, cementing its strategic pursuit of innovative, viral-based cancer immunotherapy solutions. ... Read More
Boehringer Ingelheim’s Cyltezo achieves clinical equivalence to Humira in Phase 3 psoriasis trial
German pharmaceutical giant Boehringer Ingelheim has announced a significant milestone in the treatment of moderate-to-severe chronic plaque psoriasis. Their drug, Cyltezo, a biosimilar to AbbVie's ... Read More